

Supplementary Table 1. *P53* c.215G>C, *FAS* c.-671A>G and c.-1378G>A, *FASL* c.-844C>T, *CASP3* c.-1191A>G and c.-182-247G>T single nucleotide variants and *FAS* and *CASP3* haplotypes in 109 patients with head and neck squamous cell carcinoma stratified by response rate and toxicity after treatment with cisplatin chemoradiotherapy

Variable	Vomiting		Response rate		Nephrotoxicity	
	G0	G1-G4	CR+PR	SD	G0+G1	G2-G5
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
P53 c.215G>C						
GG	17 (44.7)	25 (50.0)	35 (42.2)	4 (80.0)	26 (54.2)	13 (35.1)
GC or CC	21 (55.3)	25 (50.0)	48 (57.8)	1 (20.0)	22 (45.8)	24 (64.9)
<i>P</i> -value	0.625		0.135		0.083	
OR (95% CI)	0.81 (0.34-1.88)		0.18 (0.02-1.70)		2.18 (0.90-5.27)	
GG or GC	37 (97.4)	41 (82.0)	75 (90.4)	75 (90.4)	44 (91.7)	34 (91.9)
CC	1 (2.6)	9 (18.0)	8 (9.6)	8 (9.6)	4 (8.3)	3 (8.1)
<i>P</i> -value	0.052		0.470		0.970	
OR (95% CI)	8.12 (0.88-67.21)		2.34 (0.23-23.59)		0.97 (0.20-4.63)	
FAS c.-671A>G						
AA	13 (34.2)	17 (34.0)	25 (30.1)	1 (20.0)	14 (29.2)	13 (35.1)
AG or GG	25 (65.8)	33 (66.0)	58 (69.9)	4 (80.0)	34 (70.8)	24 (64.9)
<i>P</i> -value	0.984		0.634		0.558	
OR (95% CI)	1.00 (0.41-2.45)		1.72 (0.18-16.21)		0.76 (0.30-1.90)	
AA or AG	28 (73.7)	39 (78.0)	62 (74.7)	5 (100.0)	37 (77.1)	28 (75.7)
GG	10 (26.3)	11 (22.0)	21 (25.3)	0 (0.0)	11 (22.9)	9 (24.3)
<i>P</i> -value	0.638		NE		0.879	
OR (95% CI)	0.79 (0.29-2.11)		NE		1.08 (0.39-2.96)	
FAS c.-1378G>A						
GG	26 (68.4)	38 (76.0)	58 (69.9)	3 (60.0)	36 (75.0)	25 (67.6)
GA or AA	12 (31.6)	12 (24.0)	25 (30.1)	2 (40.0)	12 (25.0)	12 (32.4)
<i>P</i> -value	0.430		0.644		0.451	
OR (95% CI)	0.68 (0.26-1.75)		1.54 (0.24-9.83)		1.44 (0.55-3.72)	
GG or GA	34 (89.5)	48 (96.0)	77 (92.8)	5 (100.0)	46 (95.8)	33 (89.2)
AA	4 (10.5)	2 (4.0)	6 (7.2)	0 (0.0)	2 (4.2)	4 (10.8)
<i>P</i> -value	0.246		NE		0.252	
OR (95% CI)	0.35 (0.06-2.04)		NE		2.78 (0.48-16.12)	
FAS + FAS						
GA	10 (26.3)	9 (18.0)	20 (24.1)	2 (40.0)	10 (20.8)	10 (27.0)
Other haplotypes	28 (73.7)	41 (82.0)	63 (75.9)	3 (60.0)	38 (79.2)	27 (73.0)
<i>P</i> -value	0.350		0.434		0.505	
OR (95% CI)	0.61 (0.22-1.70)		2.10 (0.32-13.47)		1.40 (0.51-3.84)	
FASL c.-844C>T						

CC	11 (28.9)	15 (30.0)	28 (33.7)	0 (0.0)	12 (25.0)	11 (29.7)
CT or TT	27 (71.1)	35 (70.0)	55 (66.3)	5 (100.0)	36 (75.0)	26 (70.3)
<i>P</i> -value	0.915		NE		0.627	
OR (95% CI)	0.95 (0.37-2.40)		NE		0.78 (0.30-2.06)	
CC or CT	32 (84.2)	36 (72.0)	64 (77.1)	2 (40.0)	37 (77.1)	28 (75.7)
TT	6 (15.8)	14 (28.0)	19 (22.9)	3 (60.0)	11 (22.9)	9 (24.3)
<i>P</i> -value	0.181		0.088		0.879	
OR (95% CI)	2.07 (0.71-6.03)		5.05 (0.78-32.49)		1.08 (0.39-2.96)	
<i>CASP3</i> c.-1191A>G						
AA	12 (31.6)	23 (46.0)	35 (42.2)	35 (42.2)	17 (35.4)	18 (48.6)
AG or GG	26 (68.4)	27 (54.0)	48 (57.8)	48 (57.8)	31 (64.6)	19 (51.4)
<i>P</i> -value	0.173		0.348		0.221	
OR (95% CI)	0.54 (0.22-1.30)		2.91 (0.31-27.23)		0.57 (0.24-1.38)	
AA or AG	33 (86.8)	46 (92.0)	75 (90.4)	75 (90.4)	40 (83.3)	35 (94.6)
GG	5 (13.2)	4 (8.0)	8 (9.6)	8 (9.6)	8 (16.7)	2 (5.4)
<i>P</i> -value	0.433		0.470		0.128	
OR (95% CI)	0.57 (0.14-2.30)		2.34 (0.23-23.59)		0.28 (0.05-1.43)	
<i>CASP3</i> c.-182-247G>T						
GG	9 (23.7)	20 (40.0)	30 (36.1)	4 (80.0)	18 (37.5)	15 (40.5)
GT or TT	29 (76.3)	30 (60.0)	53 (63.9)	1 (20.0)	30 (62.5)	22 (59.5)
<i>P</i> -value	0.110		0.087		0.776	
OR (95% CI)	0.46 (0.18-1.18)		0.14 (0.01-1.32)		0.88 (0.36-2.11)	
GG or GT	31 (81.6)	45 (90.0)	73 (88.0)	73 (88.0)	42 (87.5)	32 (86.5)
TT	7 (18.4)	5 (10.0)	10 (12.0)	10 (12.0)	6 (12.5)	5 (13.5)
<i>P</i> -value	0.261		0.606		0.890	
OR (95% CI)	0.49 (0.14-1.69)		1.82 (0.18-18.00)		1.09 (0.30-3.90)	
<i>CASP3</i> + <i>CASP3</i>						
GT	18 (47.4)	14 (28.0)	27 (32.5)	0 (0.0)	15 (31.3)	10 (27.0)
Other haplotypes	20 (52.6)	36 (72.0)	56 (67.5)	5 (100.0)	33 (68.8)	27 (73.0)
<i>P</i> -value	0.064		NE		0.672	
OR (95% CI)	0.43 (0.17-1.04)		NE		0.81 (0.31-2.10)	

CR: complete response; PR: partial response; SD: stable disease; G: grade of toxicity; N: number of patients; OR: odds ratio; CI: confidence interval; NE: not evaluated. The total number of patients differed from the total quoted in the study (N = 109) because it was not possible to obtain consistent information about response rate and toxicities in some cases